challenge. 3, 4 One of the conditions associated with male aging is the andropausal syndrome (AS; other terms include androgen deficiency in the aging male and late-onset hypogonadism). 5, 6 AS refers to a clinical syndrome with characteristic psychosomatic signs and symptoms usually attributed to the age-related decline in circulating testosterone, dehydroepiandrosterone, and other male hormones. 5, 7 Although andropausal symptoms are quite common in elderly men, 8 the causal relationship between the progressively diminished serum testosterone level (and other anabolic hormones) and the symptoms affecting the aging male is still controversial. 6 Further, it is unclear whether concomitant chronic diseases (for example, cardiovascular diseases) could affect the magnitude of andropausal symptoms in the elderly.
Heart failure (HF) is one of the leading medical and socioeconomic problems in the developed countries [9] [10] [11] [12] [13] ; its prevalence progressively increases with age from 0.7% in persons aged from 45 to 54 years to 8.4% in those aged 75 years and older (United States data). 14 In Europe, HF affects more than 10% of the population aged 85 years and older, 15 and some authors describe this cardiovascular disease as a cardiogeriatric syndrome. 16 Advanced age is considered as one of the major risk factors for developing HF.
17 There are hypotheses that HF may be related to the senescence of the cardiomyocytes (aging at the cellular level associated with the shortening of the telomeres). 7 The deficiencies of anabolic hormones are common in men with systolic HF 18 and have several consequences; they are associated with reduced exercise capacity, 19 greater severity of depressive symptoms, 20 and poor patient prognosis. 18 Therefore, in this study we aimed to compare the prevalence of AS and the severity of andropausal symptoms between men with systolic HF and the local cohort of age-matched healthy men, and to investigate the clinical and hormonal determinants of the severity of andropausal symptoms in younger compared with older men with systolic HF.
PAtIents And methods study populations The study was conducted among male patients with chronic systolic HF attending the outpatient clinic or admitted electively to the tertiary referral center (Center for Heart Diseases, Military Hospital, Wrocław, Poland). The inclusion criteria were: 1) a documented history of chronic HF of ≥6 months; 2) left ventricular ejection fraction (LVEF) ≤45% assessed by echocardiography, using the Simpson's planimetric method to determine LVEF; 3) clinical stability of the patient and an unchanged list of medications for ≥1 month preceding the study. The exclusion criteria were as follows: 1) acute coronary syndrome, coronary revascularization, and/or any other major surgery within the 3 months preceding the study; 2) unplanned hospitalization due to deterioration of HF and/or any other cardiovascular reason within 1 month preceding the study; 3) any hormonal arterial hypertension, atrial fibrillation, diabetes mellitus, previous stroke, and/or transient ischemic attack, chronic obstructive pulmonary disease (COPD), and peripheral vascular disease; 6) administered medications: angiotensin-converting enzyme inhibitor or/and angiotensin receptor blocker, β-blocker, spironolactone, loop diuretic, thiazide diuretic, digoxin, statin, and acetylsalicylic acid. During the construction of multivariable models, we included all variables that had been shown to be significant (P <0.05) determinants of the severity of andropausal symptoms in the univariable analyses.
Univariable and multivariable logistic regression analyses were applied to establish the variables associated with the higher prevalence of AS (defined as described above), separately in younger (40-59 years) and older (60-80 years) age groups of men with systolic HF. In the univariable analyses, as the potential risk factors for the higher prevalence of AS we included the same groups of variables as in linear regression analyses. During the construction of multivariable models, we included all the variables that had been shown to be significant risk factors for the higher prevalence of AS in univariable models (P <0.05). A P value less than 0.05 was considered statistically significant. Statistical analyses were performed using the STATISTICA 9.1. data analysis software system (StatSoft, Inc).
results baseline characteristics of men with systolic heart failure and healthy men We examined 279 healthy men aged from 40 to 59 years (mean BMI, 27.3 ±3.6 kg/m 2 ) and 83 healthy men aged from 60 to 80 years (mean BMI, 27.6 ±3.0 kg/m 2 ). The baseline characteristics of men with HF are shown in tAble 1. Men with HF aged from 60 to 80 years had lower values of heart rate, hemo globin, WBC count, eGFR, uric acid, total cholesterol, and serum DHEAS, and higher values of serum sodium compared with men with HF aged from 40 to 59 years (all P <0.05). Men with HF aged from 60 to 80 years presented with more common ischemic etiology of HF and the prevalence of previous myocardial infarction, arterial hypertension, diabetes and COPD as well as the therapy with statin was higher in this age group (all P <0.05).
severity of andropausal symptoms in men with systolic heart failure and healthy men In the younger age group (40-59 years), the severity of sexual, somatovegetative, and all andropausal symptoms (but not psycho logical ones) was greater in men with HF compared with healthy men (all P <0.001). In the older age group (60-80 years), the severity of psycho logical, somatovegetative, and all andropausal symptoms (but not sexual ones) was similar in men with HF and healthy peers (FIGure 1).
Among men with HF, only the sexual symptoms were more severe in the older compared with the younger group of patients (P <0.001, tAble 1).
To estimate the circulating fraction of free testosterone (FT) and free E2, we also measured the serum level of sex hormone-binding globulin (SHBG) in all subjects using an immunoassay (Diagnostic Products Corp, San Francisco, California), and SHBG was expressed in nmol/l. The inter assay and intraassay variability coefficients for SHBG were 5.2% and 3.0%, respectively. The serum level of estimated FT (eFT; expressed in pg/ ml; to convert to pmol/l, multiply by 3.467) was calculated with the validated equation of Vermeulen et al. 23 The serum level of estimated free E2 (eFE2; expressed in pg/ml; to convert to pmol/l, multiply by 3.671) was calculated with the validated equation of Södergård et al.
24
Plasma level of N-terminal pro-B-type natriuretic peptide (NT-proBNP; pg/ml) was measured with an immunoassay based on electrochemiluminescence on the Elecsys 1010/2010 System (Roche Diagnostics GmbH, Mannheim, Germany). The estimated glomerular filtration rate (eGFR, ml/min/1.73 m²) was estimated using the Modification in Diet in Renal Disease equation. 25 The serum level of high-sensitivity C--reactive protein (hsCRP, mg/l) was assessed using kinetic nephelometry (Dade Behring, Siemens Healthcare Diagnostics, Inc.).
statistical analyses Most continuous variables had a normal distribution, and were expressed as a mean ± the standard deviation of the mean.
The inter group differences were tested using the t test for unpaired samples. Plasma NT-proBNP, serum DHEAS, and serum hsCRP had a skewed distribution, and were log-transformed (a natural logarithm, ln) to normalize their distribution. They were expressed as a median with lower and upper quartiles (an inter quartile range), and the intergroup differences were tested using the t test for unpaired samples for normalized values. Categorized variables were expressed as a number and a percentage, and the inter group differences were tested using the χ 2 test.
Univariable and multivariable linear regression analyses were applied to establish variables determining the severity of andropausal symptoms (3 AMS subscores for psycho logical, sexual, somatovegetative symptoms, and a total AMS score -all andropausal symptoms), separately in younger (40-59 years) and older (60-80 years) age groups of men with systolic HF. In the univariable analyses, as the potential determinants of the severity of andropausal symptoms we included: 1) anthropometric para meters: age, body mass index (BMI); 2) para meters describing the severity of HF: New York Heart Association (NYHA) functional class, LVEF, plasma NT-proBNP, serum sodium, ischemic HF etiology, heart rate, systolic blood pressure; 3) other laboratory parameters: hemo globin, white blood cells (WBC), platelets (PLT), eGFR, plasma total cholesterol, serum uric acid, serum hsCRP; 4) serum hormones: TT, eFT, DHEAS, IGF-1, E2, eFE2; 5) major comorbidities: previous myocardial infarction, and E2 and with the therapy with loop diuretic; the more severe sexual symptoms: with low LVEF and hemo globin; the more severe somatovegetative symptoms: with low serum TT; and the more severe andropausal symptoms (in total): with low serum TT and the therapy with loop diuretic (all P <0.05, Prevalence of andropausal syndrome in men with systolic heart failure and healthy men In the age group of 40 to 59 years, the prevalence of AS was higher in men with HF compared with healthy men (28% vs. 7%, P <0.001, FIGure 2). In the age group of 60 to 80 years, the prevalence of AS did not differ between men with HF and healthy peers (31% vs. 40%, P = 0.22, FIGure 2).
Among men with systolic HF, the prevalence of AS was similar in subjects aged from 40 to 59 and those aged from 60 to 80 years (P = 0.53, determinants of the severity of andropausal symptoms in younger and older men with systolic heart failure In men with systolic HF aged from 40 to 59 years, in multivariable linear regression models, the more severe psycho logical symptoms were independently associated with the advanced NYHA class, low hemo globin, high PLT count, and with the presence of COPD; the more severe sexual symptoms: with the advanced NYHA class, low hemo globin, and the therapy with spironolactone; the more severe somatovegetative symptoms: with the advanced NYHA class and low hemo globin; and the more severe andropausal symptoms (in total): with the advanced NYHA class; low hemo globin, and the presence of COPD (all P <0.05, tAble 2).
In men with systolic HF aged from 60 to 80 years, in multivariable linear regression models, the more severe psycho logical symptoms were independently associated with high total cholesterol andropausal syndrome, n (%) 68 (29) 33 (28) 35 (31) Data are presented as a mean ± standard deviation of the mean, a median (with lower and upper quartiles) or number (percentage), where appropriate. Andropausal syndrome was diagnosed according to Daig et al., 20 if the Aging Males' Symptoms Rating Scale total score was ≥50 points.
a P <0.05, b P <0.01, c P <0.001
For details see the "Methods" section. To convert the values for total cholesterol to mmol/l, multiply by 0.0259; uric acid to µmol/l by 59.48; TT to nmol/l by 3.467; eFT to pmol/l by 3.467; DHEAS to µmol/l by 0.00271; IGF-1 to nmol/l by 0.131; E2 and eFE2 to pmol/l by 3.671.
Abbreviations: ACEI -angiotensin-converting enzyme inhibitor, ARB -angiotensin receptor blocker, ASA -acetylsalicylic acid, BMI -body mass index, CAD -coronary artery disease, COPD -chronic obstructive pulmonary disease, DHEAS -dehydroepiandrosterone sulphate, eFE2 -estimated free estradiol, eFT -estimated free testosterone, eGFR -estimated glomerular filtration rate, E2 -estradiol, HF -heart failure, HR -heart rate, hsCRPhigh-sensitive C-reactive protein, IGF-1 -insulin-like growth factor 1, LVEF -left ventricular ejection fraction, NT-proBNP -N-terminal pro-B-type natriuretic peptide, NYHA -New York Heart Association, PLT -platelets, SBP -systolic blood pressure, TIA -transient ischemic attack, TT -total testosterone, WBC -white blood cells Abbreviations: ln -natural logarithm, others -see tAble 1 risk factors associated with the higher prevalence of andropausal syndrome in younger and older men with systolic heart failure In men with systolic HF aged from 40 to 59 years, in multivariable logistic regression models, the following variables were independently associated with the higher prevalence of AS: the advanced NYHA class, low hemoglobin and serum DHEAS, and high PLT count (all P <0.05). In men aged from 60 to 80 years only reduced hemo globin was borderline related to the higher prevalence of AS (P = 0.07) (tAble 4 and 5).
dIscussIon There are two major findings arising from the present study. Firstly, AS was very common in male patients with systolic HF. The prevalence of AS was 4 times higher in men with systolic chronic HF aged from 40 to 59 years compared with healthy men. In contrast, among subjects aged from 60 to 80 years, there was no difference in the prevalence of AS between men with vs. those without HF. Secondly, clinical and hormonal determinants of AS differed between the younger and older age groups of male patients with HF. To the best of our knowledge, this is the first study reporting the prevalence of AS in chronic cardiovascular disease, while AS and andropausal symptoms have been documented in men with other chronic diseases, such as type 2 diabetes, 26 osteoporosis, 27 and in men treated with hormonal ablation therapy for prostate cancer. 28 We have shown that AS (diagnosed based on the severity of andropausal symptoms using the Polish version of the AMS scale with the highest cut-off, that is, the total AMS score 50 points or more) 21, 22 is common in men with HF aged from 40 to 59 years, affecting 28% of these patients, which is significantly higher than in the age-matched local healthy male population (7%). Of note, the prevalence of AS in Polish healthy men in the age group of 40 to 59 years is similar as in a population sample of 959 German men aged from 40 to 69 years (7%), which was used to standardize the AMS scale. 21, 22 In contrast, in the age group of 60 to 80 years, we found no differences either in the severity of andropausal symptoms (the subscores for 2 symptom clusters and the total AMS score) nor the prevalence of AS between men with systolic HF and healthy (although elderly) male subjects. We hypothesize that the occurrence of HF, a serious disease with multiple endocrine derangements, 18 at a relatively younger age markedly accelerates and enhances the process of male aging, which is associated with the development of andropausal symptoms.
In our study, we have focused exclusively on the clinical syndrome of self-reported andropausal symptoms (that is, associated with male aging) included and assessed in the validated AMS scale. 21, 22 The applied methodo logical approach has enabled us not only to assess the prevalence of AS in men with systolic HF, but also to investigate whether this pathology is associated with hormonal milieu, including androgen deficiencies. We need to emphasize that we have not investigated the late-onset hypogonadism, the definition of which is based on the presence not only of the andropausal symptoms, but also the laboratory confirmation of gonadal hypogonadism. 6 We have observed some associations between the severity of andropausal symptoms and the hormonal status; however, the effects were not as strong as one might expect. There is no consensus regarding the causal relationships between androgen deficiencies and andropausal symptoms in aging men. 5,6 Morley et al. 29 observed that in 148 men aged from 23 to 80 years free and bioavailable testosterone (but not TT) inversely correlated with a total AMS score. Kratzik et al. 30 showed that in 664 manual workers aged from 40 to 60 years, high serum TT level reduced the risk for the presence of severe psycho logical andropausal symptoms. However, these findings are not unequivocal. 31, 32 In men with HF aged from 40 to 59 years, DHEAS deficiency was associated with the higher prevalence of AS, while in those aged from 60 to 80 years reduced serum TT was accompanied by severe andropausal symptoms (high total AMS score). It should be emphasized that, beyond myocardial dysfunction, excessive sympathoexcitation and skeletal myopathy, 33 HF is characterized by the presence of marked anabolic deficiencies (DHEAS, TT, and IGF-1) with several unfavorable consequences (high mortality, impaired exercise capacity, augmented depressive symptoms). [18] [19] [20] This study provides another evidence on unfavorable effects of depleted androgen axes in men with systolic HF. These relationships are further supported by the observation that the therapy with spironolactone was independently related to the more severe sexual symptoms in male patients aged from 40 to 59 years. This finding is consistent with the available data on the antiandrogenic effect of this unselective aldosterone antagonist, due to its inter ference with Data are presented as a mean ± a standard deviation of the mean, a median (with lower and upper quartiles) or n (with %), where appropriate. All variables shown to be significant (P <0.05) risk factors for the presence of andropausal syndrome in the univariable models were included in the multivariable models. Andropausal syndrome was diagnosed according to Daig et al., 20 if Aging Males' Symptoms Rating Scale total score was ≥50 and 2 the testosterone production, as well as the antagonism with androgen receptors in target tissues. 34 In conclusion, AS affects almost one-third of men with HF, regardless of the age group. Clinical and hormonal determinants differ between younger and older male patients. There are some links between androgen deficiencies (TT, DHEAS), antiandrogen therapy (spironolactone), and andropausal symptoms. Endocrino logical and sexual counseling is recommended in men with HF. Further studies are needed to establish whether the presence of AS is related to the worse outcome in these patients, and whether the androgen supplementation would reduce the severity of andropausal symptoms. Data are presented as a mean ± a standard deviation of the mean, a median (with lower and upper quartiles) or n (with %), where appropriate. All variables shown to be significant (P <0.05) risk factors for the presence of andropausal syndrome in the univariable models were included in the multivariable models. Andropausal syndrome was diagnosed according to Daig et al., 20 if Aging Males' Symptoms Rating Scale total score was ≥50 
